
CLCS
Healthcare · Biotechnology · $29.9M market cap
$0.44000.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 7, 2024 | After the close | — | -0.04 | — |
| Aug 19, 2024 | Before the open | — | -0.04 | — |
| Nov 9, 2023 | After the close | — | -0.04 | — |
| Sep 19, 2023 | Before the open | — | -0.04 | — |
| Nov 2, 2022 | Time not confirmed | — | -0.05 | — |
| Apr 15, 2022 | Time not confirmed | — | -0.03 | — |
| Nov 15, 2021 | Time not confirmed | — | -0.06 | — |
| Aug 12, 2021 | Time not confirmed | — | -0.05 | — |
| Apr 15, 2021 | Time not confirmed | — | -0.06 | — |
| Mar 31, 2021 | Time not confirmed | — | -0.05 | — |
| Nov 13, 2020 | Time not confirmed | — | -0.05 | — |
| Aug 14, 2020 | Time not confirmed | — | -0.05 | — |
| May 15, 2020 | Time not confirmed | — | -0.04 | — |
| Mar 30, 2020 |
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia,…
| Time not confirmed |
| — |
| -0.03 |
| — |
| Nov 14, 2019 | Time not confirmed | — | -0.06 | — |
| Aug 14, 2019 | Time not confirmed | — | -0.04 | — |
| Apr 1, 2019 | Time not confirmed | — | -0.02 | — |
| Oct 18, 2018 | Time not confirmed | — | -0.02 | — |
| Jul 25, 2018 | Time not confirmed | — | -0.04 | — |
| Jun 30, 2018 | Time not confirmed | — | -0.02 | — |
| Mar 31, 2018 | Time not confirmed | — | -0.03 | — |